Files

Abstract

The prognosis for patients with the genetic neurological disorder Huntington's disease (HD) is incredibly poor. HD onsets in midlife, causes a variety of severe and debilitating symptoms, progresses over 10-15 years, and always leads to death. There are currently no treatments that can slow the progression of the disease in any way. Thus, there is tremendous need to discover new therapeutic approaches that can slow or halt disease progression and thereby improve quality of life for patients. In the studies presented here, I characterized the roles of glucocorticoids and the anterior cingulate cortex in HD symptomology, with the overarching goal of assessing the suitability of these two systems as possible points of therapeutic intervention for HD.

Details

PDF

Statistics

from
to
Export
Download Full History